Table 3.
Changes from Baseline to Week 26 in Inflammatory Markers
| Variables | Baseline | At 26 Weeks | Absolute Difference2 |
Relative Difference3 |
P-Value4 | ||
|---|---|---|---|---|---|---|---|
| Tesamorelin (N=273) |
Placebo (N=137) |
Tesamorelin (N=273) |
Placebo (N=137) |
||||
| Change from Baseline (Percent) | |||||||
| PAI-1 (ng/mL) | 34.9 ± 19.8 | 35.0 ± 18.4 | −2.5 ± 16.9 (3.5)1 | −1.0 ± 17.3 (8.5) | −1.5 | −5.0 | 0.34 |
| tPA (ng/mL) | 9.7 ± 4.1 | 9.7 ± 3.7 | −2.2 ± 2.5 (−21.6)1 | −1.6 ± 2.9 (−14.2)1 | −0.6 | −7.4 | 0.03 |
| CRP (mg/L)* | 4.6 ± 9.4 | 4.4 ± 6.6 | −0.4 ± 11.9 (23.9) | 0.4 ± 7.9 (75.0) | −0.8 | −51.1 | 0.54 |
| Adiponectin (µg/mL)* | 5.3 ± 3.7 | 5.4 ± 3.2 | 0.5 ± 2.7 (12.4)1 | −0.1 ± 1.3 (2.4) | 0.6 | 10 | 0.03 |
Data are reported as mean ± SD, unless otherwise indicated.
*
Data previously published in [15].
1
P <0.05 for the change from baseline to Week 26 within the tesamorelin group and the placebo group.
2
The values are for the difference between the changes from baseline in the tesamorelin group and the placebo group.
3
The values are for the difference between the percent change from baseline in the tesamorelin group and the placebo group.
4
P values are for the comparison between the changes from baseline in the tesamorelin group and the placebo group.